rolofylline has been researched along with Chronic Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biegus, J; Bloomfield, DM; Cleland, JG; Cotter, G; Davison, BA; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Postmus, D; Teerlink, JR; Valente, MA; Voors, AA | 1 |
| Givertz, MM; Slawsky, MT | 1 |
1 review(s) available for rolofylline and Chronic Kidney Diseases
| Article | Year |
|---|---|
Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure.
Topics: Adenosine A1 Receptor Antagonists; Animals; Cardiovascular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Renal Insufficiency, Chronic; Syndrome; Xanthines | 2009 |
1 other study(ies) available for rolofylline and Chronic Kidney Diseases
| Article | Year |
|---|---|
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study.
Topics: Acute Disease; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Disease Progression; Diuretics; Female; Heart Failure; Humans; Liver Function Tests; Male; Middle Aged; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Serum Albumin; Xanthines | 2016 |